2051. Plasmid Promiscuity Explains High Endemicity of KPC-2 Among Colombian Enterobacteriaceae
Session: Poster Abstract Session: Diagnostics - Bacterial Identification & Resistance
Saturday, October 7, 2017
Room: Poster Hall CD

Background: Carbapenemase-producing Enterobacteriaceae (CPE) currently pose a significant global public health threat. KPC carbapenemases are highly endemic in Colombia mostly among Enterobacteriaceae. In Klebsiella pneumoniae (Kpn), horizontal transfer of genes encoding KPC and expansion of isolates belonging to clonal group (CG) 258 resulted in epidemic levels of carbapenemase-producing Kpn. We aimed to understand the dynamics of transmission of KPC-genes among CPE infecting and colonizing patients in an endemic area of Colombia.


Methods: We conducted a surveillance study in 3 hospitals around Medellin, Antioquia (November 2013 to October 2015) that included patients colonized and infected (by physician criteria) with CPE. The isolates were collected, identified and typed initially using rep-PCR. A subset of isolates were chosen for Whole Genome Sequencing on the Illumina platform based on initial molecular characterization. De-novo assembly and maximum likelihood phylogenetic analyses were performed in all sequenced isolates.


Results: A total of 131 KPC-producing Enterobacteriaceae isolates were recovered from 77 colonized and 29 infected patients. A total of 76 selected isolates were sequenced. In Kpn, compartmentalization of KPC-3 within CG258 was observed, whereas KPC-2 was identified in different genetic backgrounds but not in CG258. In E. coli, blaKPC-2 was found in two clusters belonging to ST131 and ST349. In one hospital both Kpn (ST36,15,101,140, 502) and E. coli shared a 56 Kb plasmid harboring blaKPC-2 with high degree of identity to the conjugative IncN plasmid N3. The blaKPC-2 gene was found within a variation of Tn4401b harboring ISKpn6 and carrying both a Tn3-transposase and a resolvase. E. cloacae, C. freundii and S. marcescens only harbored KPC-2 (and not KPC-3) within the same Tn4401b structure.  


Conclusion: The KPC epidemic in an area of high endemicity in Colombia is driven by horizontal transfer of plasmids harboring blaKPC-2 among members of the Enterobacteriaceae family. These findings are consistent with a KPC-plasmid epidemic rather than clonal expansion of a successful genetic lineage. Controlling the KPC epidemic in Colombia would be challenging and is likely influenced by antibiotic consumption rather than patient to patient transmission.


Ana Mercedes Rada, MSc1,2, Elsa De La Cadena, MSc3, Nataly Orozco, MSc1, Carlos Agudelo Restrepo, MD, MSc4, Cesar Capataz, MD5, Marcela N Perenguez, BSc3, Cristhian Hernández-Gómez, MSc3, Christian Pallares, MD, MSc6, Paola Porras, BSc7, Javier Ardila, MSc7, Rafael Ríos, MSc8, Jinnethe Reyes, PhD8, Lorena Diaz, PhD7, Adriana Correa, PhD3, Maria Virginia Villegas, MD, MSc, FIDSA3,9, Cesar Arias, MD, PhD, FIDSA8,10 and Eliana Restrepo, PhD1, (1)Universidad de Antioquia, Medellín, Colombia, (2)Institución Universitaria Colegio Mayor de Antioquia, Medellín, Colombia, (3)International Center for Medical Research and Training CIDEIM, Cali, Colombia, (4)Clínica Universitaria Bolivariana, Medellín, Colombia, (5)Fundación Clínica del Norte, Bello, Colombia, (6)Bacterial Resistance and Hospital Epidemiology, International Center for Medical Research and Training CIDEIM, Cali, Colombia, (7)Molecular Genetics and Antimicrobial Resistance Unit - International Center for Microbial Genomics, Universidad El Bosque, Bogota, Colombia, (8)Universidad El Bosque, Bogota, Colombia, (9)Antimicrobial Resistance and Hospital Epidemiology, Universidad El Bosque, Bogotá, Colombia, (10)Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), University of Texas McGovern Medical School, Houston, TX


A. M. Rada, COLCIENCIAS: Student , Research grant and Research support

E. De La Cadena, None

N. Orozco, COLCIENCIAS: Research Contractor , Salary

C. Agudelo Restrepo, None

C. Capataz, None

M. N. Perenguez, None

C. Hernández-Gómez, Merck Sharp & Dohme, Pfizer: Consultant , Consulting fee

C. Pallares, Merck Sharp & Dohme, Pfizer: Consultant , Consulting fee

P. Porras, None

J. Ardila, None

R. Ríos, None

J. Reyes, None

L. Diaz, None

A. Correa, None

M. V. Villegas, Merck Sharp & Dohme, Pfizer: Consultant , Consulting fee and Research support

C. Arias, None

E. Restrepo, COLCIENCIAS: Investigator , Research support

<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.